Search Results for: SRPT
One of Cathie Wood's Ark Invest funds sold over 675,000 shares of Galileo Acquisition on June 17.
Published:
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) saw its shares make a handy gain on Monday after the firm received an upgrade from Morgan Stanley. The driving force behind this upgrade is Sarepta’s...
Published:
Last Updated:
Sarepta shares jumped last week on news that the company reached a licensing deal with Roche. While investors saw about a five-point bump from this news, one analyst sees much more upside for this...
Published:
One of Cathie Wood's Ark Invest funds sold over 40,000 shares of Baidu on August 18.
Published:
This report was sent to Briefing.com subscribers earlier today. Upgrades: > Coupang (CPNG) upgraded to Buy from Hold at Deutsche Bank; tgt $20 > Empire State Realty Trust (ESRT) upgraded to Buy...
Published:
One of Cathie Wood's Ark Invest funds sold over 225,000 shares of Takeda Pharma on June 15.
Published:
One of Cathie Wood's Ark Invest funds sold over 350,000 shares of Takeda Pharmaceutical on June 16.
Published:
Selecta Biosciences and Sarepta Therapeutics have announced that they had entered into a research license and option agreement.
Published:
Sarepta Therapeutics plunged early on Friday as the result of a failed clinical trial by BioMarin Pharmaceutical.
Published:
Last Updated:
Source: Photo by Spencer Platt/Getty ImagesThe stock market is up slightly Wednesday, with the Dow Jones Industrial Average up 0.07%, the Nasdaq up 0.24% and the S&P 500 up 0.13%. Today’s winners...
Published:
Last Updated:
Catabasis Pharmaceuticals shares skyrocketed on Thursday following an announcement that it would be partnering with Sarepta Therapeutics for a joint research collaboration.
Published:
Last Updated:
One of Cathie Wood's ARK Invest exchange-traded funds sold nearly 24,000 shares of Boeing on September 7.
Published:
Sarepta Therapeutics shares skyrocketed on Tuesday after the firm presented positive preliminary results from its midstage Duchenne muscular dystrophy trial.
Published:
Last Updated:
Sarepta Therapeutics closed out Wednesday with its shares up over 25% following positive developments surrounding eteplirsen, its treatment of Duchenne muscular dystrophy.
Published:
Last Updated:
Pfizer released initial clinical data from its Phase 1b gene therapy study for Duchenne muscular dystrophy. While these results did not necessarily live up to expectations, there is a winner in this.
Published: